Please contact the corresponding author on questions related to a tentative English version of the Wise List 2010.
The ‘Wise List’– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm
Article first published online: 18 MAR 2011
© 2011 The Authors. Basic & Clinical Pharmacology & Toxicology © 2011 Nordic Pharmacological Society
Basic & Clinical Pharmacology & Toxicology
Volume 108, Issue 4, pages 224–233, April 2011
How to Cite
Gustafsson, L. L., Wettermark, B., Godman, B., Andersén-Karlsson, E., Bergman, U., Hasselström, J., Hensjö, L.-O., Hjemdahl, P., Jägre, I., Julander, M., Ringertz, B., Schmidt, D., Sjöberg, S., Sjöqvist, F., Stiller, C.-O., Törnqvist, E., Tryselius, R., Vitols, S., von Bahr, C. and for the Regional Drug Expert Consortium (2011), The ‘Wise List’– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. Basic & Clinical Pharmacology & Toxicology, 108: 224–233. doi: 10.1111/j.1742-7843.2011.00682.x
The Regional Drug Expert Consortium also includes Peter Aspelin, Jonas Bergh, Peter Ekman, Carl-Gustaf Elinder, Johan Franck, Urban Hellgren, Angelica L. Hirschberg, Seher Korkmaz, Michael Lagerkranser, Gerd Lärfars, Lena Lundeberg, Rickard Malmström, Åke Örtqvist, Marie-Louise Ovesjö, Georgios Panagiotidis, Jan Persson, Peter M. Persson, Michael Runold, Gunilla Sundelin, Leif Tallstedt, Matti Viitanen, Mia von Euler, Katarina Wide.
- Issue published online: 18 MAR 2011
- Article first published online: 18 MAR 2011
- (Received 12 September 2010; Accepted 4 January 2011)
Abstract: The aim was to present and evaluate the impact of a comprehensive strategy over 10 years to select, communicate and achieve adherence to essential drug recommendations (EDR) in ambulatory care in a metropolitan healthcare region. EDRs were issued and launched as a ‘Wise List’ by the regional Drug and Therapeutics Committee in Stockholm. This study presents the concept by: (i) documenting the process for selecting, communicating and monitoring the impact of the ‘Wise List’; (ii) analysing the variation in the number of drug substances recommended between 2000 and 2010; (iii) assessing the attitudes to the ‘Wise List’ among prescribers and the public; (iv) evaluating the adherence to recommendations between 2003 and 2009. The ‘Wise List’ consistently contained 200 drug substances for treating common diseases. The drugs were selected based on their efficacy, safety, suitability and cost-effectiveness. The ‘Wise List’ was known among one-third of a surveyed sample of the public in 2002 after initial marketing campaigns. All surveyed prescribers knew about the concept and 81% found the recommendations trustworthy in 2005. Adherence to recommendations increased from 69% in 1999 to 77% in 2009. In primary care, adherence increased from 83% to 87% from 2003 to 2009. The coefficient of variation (CV%) decreased from 6.1% to 3.8% for 156 healthcare centres between these years. The acceptance of the ‘Wise List’ in terms of trust among physicians and among the public and increased adherence may be explained by clear criteria for drug recommendations, a comprehensive communication strategy, electronic access to recommendations, continuous medical education and involvement of professional networks and patients.